Cargando…

Cost-effectiveness of hospice-based palliative care in Kazakhstan

BACKGROUND: According to the Quality of Death Index, Kazakhstan ranks 50th out of 80 countries assessed. Currently, some form of inpatient end-of life care in Kazakhstan is provided by only 9 hospices, palliative care units and mobile teams. In 2020, the total number of palliative care beds did not...

Descripción completa

Detalles Bibliográficos
Autores principales: Salikhanov, I, Crape, B, Wieser, S, Katapodi, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833642/
http://dx.doi.org/10.1093/eurpub/ckac131.241
_version_ 1784868288133595136
author Salikhanov, I
Crape, B
Wieser, S
Katapodi, M
author_facet Salikhanov, I
Crape, B
Wieser, S
Katapodi, M
author_sort Salikhanov, I
collection PubMed
description BACKGROUND: According to the Quality of Death Index, Kazakhstan ranks 50th out of 80 countries assessed. Currently, some form of inpatient end-of life care in Kazakhstan is provided by only 9 hospices, palliative care units and mobile teams. In 2020, the total number of palliative care beds did not exceed 980 across the country, while around 135,000 patients need palliative care at any given time. Objective: To assess the effectiveness and cost-effectiveness of hospice-based palliative care for cancer patients compared to usual hospital care in cancer centers across Kazakhstan from societal perspective. METHODS: A total of 182 family caregivers were recruited, 104 in a hospice group and 78 in a control (palliative units). Patients’ state of health and family caregivers’ burden been measured using Palliative Outcome Scale (POS) and Zarit Burden Inventory (ZBI) on 14th day of the inpatient palliative care. Direct and indirect medical costs as well as family caregivers’ out-of-pocket expenses associated with the care has been collected. The cost-effectiveness analysis was conducted by calculating the difference between mean cost of treatment, including OOPs, over 14 days of treatment. Uncertainty around the cost-effectiveness estimates was explored by generating 10,000 resamples using bootstrapping. RESULTS: At 14 days, patients’ mean quality of life was 2,4 points better (95% CI: 0,06 - 4,9) in the hospice group compared to the control. Family caregiver burden was 4,6 points better in the hospice group (95% CI: -0,26 - 9.3). Mean treatment costs, including direct medical costs and out-of-pocket expenditures over 14 days were $31 lower for the hospice group (95% CI: $29 - $32). There was a significant correlation between the total cost of treatment and patients’ quality of life (rxy = 0,58; p < 0,01). The cost-effectiveness plane graphically represents 10,000 replications, 85% of them showed that hospice care has better outcomes and lower costs than the control group. KEY MESSAGES: • Hospice-based palliative care is cost-effective compared to the care provided in palliative units of cancer centers. • There is a significant correlation between patients’ quality of life and family caregivers’ burden.
format Online
Article
Text
id pubmed-9833642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98336422023-01-12 Cost-effectiveness of hospice-based palliative care in Kazakhstan Salikhanov, I Crape, B Wieser, S Katapodi, M Eur J Public Health Poster Displays BACKGROUND: According to the Quality of Death Index, Kazakhstan ranks 50th out of 80 countries assessed. Currently, some form of inpatient end-of life care in Kazakhstan is provided by only 9 hospices, palliative care units and mobile teams. In 2020, the total number of palliative care beds did not exceed 980 across the country, while around 135,000 patients need palliative care at any given time. Objective: To assess the effectiveness and cost-effectiveness of hospice-based palliative care for cancer patients compared to usual hospital care in cancer centers across Kazakhstan from societal perspective. METHODS: A total of 182 family caregivers were recruited, 104 in a hospice group and 78 in a control (palliative units). Patients’ state of health and family caregivers’ burden been measured using Palliative Outcome Scale (POS) and Zarit Burden Inventory (ZBI) on 14th day of the inpatient palliative care. Direct and indirect medical costs as well as family caregivers’ out-of-pocket expenses associated with the care has been collected. The cost-effectiveness analysis was conducted by calculating the difference between mean cost of treatment, including OOPs, over 14 days of treatment. Uncertainty around the cost-effectiveness estimates was explored by generating 10,000 resamples using bootstrapping. RESULTS: At 14 days, patients’ mean quality of life was 2,4 points better (95% CI: 0,06 - 4,9) in the hospice group compared to the control. Family caregiver burden was 4,6 points better in the hospice group (95% CI: -0,26 - 9.3). Mean treatment costs, including direct medical costs and out-of-pocket expenditures over 14 days were $31 lower for the hospice group (95% CI: $29 - $32). There was a significant correlation between the total cost of treatment and patients’ quality of life (rxy = 0,58; p < 0,01). The cost-effectiveness plane graphically represents 10,000 replications, 85% of them showed that hospice care has better outcomes and lower costs than the control group. KEY MESSAGES: • Hospice-based palliative care is cost-effective compared to the care provided in palliative units of cancer centers. • There is a significant correlation between patients’ quality of life and family caregivers’ burden. Oxford University Press 2022-10-25 /pmc/articles/PMC9833642/ http://dx.doi.org/10.1093/eurpub/ckac131.241 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Displays
Salikhanov, I
Crape, B
Wieser, S
Katapodi, M
Cost-effectiveness of hospice-based palliative care in Kazakhstan
title Cost-effectiveness of hospice-based palliative care in Kazakhstan
title_full Cost-effectiveness of hospice-based palliative care in Kazakhstan
title_fullStr Cost-effectiveness of hospice-based palliative care in Kazakhstan
title_full_unstemmed Cost-effectiveness of hospice-based palliative care in Kazakhstan
title_short Cost-effectiveness of hospice-based palliative care in Kazakhstan
title_sort cost-effectiveness of hospice-based palliative care in kazakhstan
topic Poster Displays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833642/
http://dx.doi.org/10.1093/eurpub/ckac131.241
work_keys_str_mv AT salikhanovi costeffectivenessofhospicebasedpalliativecareinkazakhstan
AT crapeb costeffectivenessofhospicebasedpalliativecareinkazakhstan
AT wiesers costeffectivenessofhospicebasedpalliativecareinkazakhstan
AT katapodim costeffectivenessofhospicebasedpalliativecareinkazakhstan